

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT Pursuant  
to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **January 6, 2016**

**Enzo Biochem, Inc.**  
(Exact Name of Registrant as Specified in Its Charter)

**New York**  
(State or Other Jurisdiction of Incorporation)

**001-09974**  
(Commission File Number)

**13-2866202**  
(IRS Employer Identification No.)

**527 Madison Avenue**  
**New York, New York**  
(Address of Principal Executive Offices)

**10022**  
(Zip Code)

**(212) 583-0100**  
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01 Other events**

On January 6, 2016, Enzo Biochem, Inc. announced that it had reached and finalized a settlement with Agilent Technologies, Inc. involving payment of \$9 million to Enzo in an infringement action brought by Enzo regarding its U.S. Patent No. 7,064,197.

This settlement resolving the disputes between Enzo and Agilent impacts only one of 11 cases originally brought by Enzo in the United States District Court for the District of Delaware alleging patent infringements against various companies, eight of which remain pending.

**Item 9.01. Financial Statements and Exhibits.****(d) Exhibits.**

99.1 Press Release of Enzo Biochem, Inc., dated January 6, 2016

---

**SIGNATURES**

---

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: January 6, 2016

By: /s/ Barry W. Weiner  
Barry W. Weiner  
President



news  
release

Enzo Biochem, Inc.  
527 Madison Avenue  
New York, NY 10022

For Immediate Release

**Enzo Biochem Reaches \$9 Million Patent Infringement Settlement with Agilent Technologies, Inc.**

**Resolved Suit Involves One of 11 Infringement Cases Brought in Delaware Federal District Court, Eight of Which Remain Pending**

NEW YORK, NY, January 6, 2016 -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has reached and finalized a settlement with Agilent Technologies, Inc. (NYSE:A) involving payment of \$9 million to Enzo in an infringement action brought by Enzo regarding its U.S. Patent No. 7,064,197.

Today's settlement resolving the disputes between Enzo and Agilent impacts only one of 11 cases originally brought by Enzo in the United States District Court for the District of Delaware alleging patent infringements against various companies, eight of which remain pending.

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies. *Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company's Form 10-K for the fiscal year ended July 31, 2015. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.*

###

**Contact:**

**For Enzo Biochem, Inc.**

Steven Anreder  
Anreder & Company  
212-532-3232  
[steven.anreder@anreder.com](mailto:steven.anreder@anreder.com)

or

Michael Wachs  
CEOcast, Inc.  
212-732-4300  
[mwachs@ceocast.com](mailto:mwachs@ceocast.com)